RNA polymerase II, I and III subunit LGenealiases: RBP10 · RPABC5 · RPB10 · RPB10beta · RPB7.6 · hRPB7.6
Q-omics provides the consensus-scored POLR2L profile across patient tissues and cancer cell-line models. POLR2L expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, POLR2L is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, POLR2L protein abundance shows 24,122 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, LIHC, and GBM as cancer lineages where POLR2L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR2L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR2L survival associations across molecular data types. POLR2L RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR2L RNA expression–survival associations across cancer types. High POLR2L expression shows unfavorable associations in ACC, KICH, LIHC, LGG, HNSC and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for POLR2L RNA expression.
This table summarizes POLR2L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for POLR2L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR2L shows lower tumor expression in LUSC, LUAD and KICH and higher tumor expression in LIHC, COAD and UCEC. The LIHC box plot shows higher POLR2L RNA expression in tumor versus normal tissue (log2 FC = +1.202, t-test p < 0.001).
This table shows molecular features associated with POLR2L in patient tissues and cancer cell lines. In patient samples, POLR2L shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, POLR2L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
